Edit Organization: Cancer Tissue Engineering Collaborative

Free text:

'''Cancer Tissue Engineering Collaborative (TEC)''' is a research program within the National Cancer Institute (NCI), initiated in 2016 to advance cancer research through state-of-the-art tissue-engineered technologies, administered by NCI’s Division of Cancer Biology. Operating from NCI’s Shady Grove campus in Rockville, Maryland, TEC funds multidisciplinary projects integrating cancer biology with regenerative medicine, biomaterials, and bioengineering, supporting over a dozen research teams to develop 3D biomimetic models that replicate tumor microenvironments, with applications in understanding metastasis, drug response, and tumor progression. {{Official URL (simple)|url=https://www.cancer.gov/about-nci/organization/dcb/research-programs/tec}} ==Mission== The Cancer Tissue Engineering Collaborative aims to enhance cancer research by catalyzing the creation of advanced, well-characterized tissue-engineered systems that mimic cancer biology, enabling exploration of phenomena difficult to study in vivo. It promotes collaboration across fields to broaden these models across cancer types, aligning with NCI’s goals to improve prevention, detection, and treatment through innovative research platforms.<ref>{{cite web |url=https://www.cancer.gov/about-nci/organization/dcb/research-programs/tec |title=Cancer Tissue Engineering Collaborative |publisher=National Cancer Institute |access-date=February 22, 2025}}</ref> ==Parent organization== The Cancer Tissue Engineering Collaborative operates under the [[National Cancer Institute]], specifically within the Division of Cancer Biology, part of the [[National Institutes of Health]], under the Department of Health and Human Services.<ref>{{cite web |url=https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-cancer-institute-nci |title=National Cancer Institute |publisher=National Institutes of Health |access-date=February 22, 2025}}</ref> ==Legislation== TEC was not established by specific legislation but operates under NCI’s authority from the [https://www.govinfo.gov/content/pkg/STATUTE-51/pdf/STATUTE-51-Pg162.pdf National Cancer Act of 1937], expanded by the [https://www.govinfo.gov/content/pkg/STATUTE-85/pdf/STATUTE-85-Pg774.pdf National Cancer Act of 1971], with funding formalized through notices like PAR-25-171 in 2016.<ref>{{cite web |url=https://grants.nih.gov/grants/guide/pa-files/PAR-25-171.html |title=PAR-25-171 |publisher=National Institutes of Health |access-date=February 22, 2025}}</ref> ==Partners== TEC collaborates with: *NCI Physical Sciences-Oncology Network (PS-ON) for meetings and insights *Academic institutions (e.g., MIT, USC) for funded projects *Tissue engineering and cancer biology researchers nationwide<ref>{{cite web |url=https://www.cancer.gov/about-nci/organization/dcb/research-programs/tec |title=Cancer Tissue Engineering Collaborative |publisher=National Cancer Institute |access-date=February 22, 2025}}</ref> ==Number of employees== TEC’s staff size is not specified; it’s managed by NCI Division of Cancer Biology personnel, supporting a network of funded investigators rather than employing a dedicated team.<ref>{{cite web |url=https://www.cancer.gov/about-nci/organization/dcb |title=Division of Cancer Biology |publisher=National Cancer Institute |access-date=February 22, 2025}}</ref> ==Organization structure== TEC is a program, not a standalone center: *Program Leadership oversees funding and collaboration. *Research Teams conduct projects under R01 grants. ===Leader=== The Cancer Tissue Engineering Collaborative is headed by a Program Director within NCI’s Division of Cancer Biology; the current leader is not individually named in public records.<ref>{{cite web |url=https://www.cancer.gov/about-nci/organization/dcb/research-programs/tec |title=Cancer Tissue Engineering Collaborative |publisher=National Cancer Institute |access-date=February 22, 2025}}</ref> ===Divisions=== TEC has no formal divisions but supports: *Funded Research Projects (e.g., metastasis, immunotherapy models).<ref>{{cite web |url=https://www.cancer.gov/about-nci/organization/dcb/research-programs/tec/advances |title=Research Advances |publisher=National Cancer Institute |access-date=February 22, 2025}}</ref> *Associate Membership for unfunded collaborators. ==List of programs== TEC oversees: *Cancer TEC R01 Grants - https://www.cancer.gov/about-nci/organization/dcb/research-programs/tec<ref>{{cite web |url=https://grants.nih.gov/grants/guide/pa-files/PAR-25-171.html |title=PAR-25-171 |publisher=National Institutes of Health |access-date=February 22, 2025}}</ref> *Associate Membership Program *Collaborative Workshops with PS-ON ==Last total enacted budget== TEC’s budget is not separately itemized; it’s funded within NCI’s $7.2B FY 2025 request, with individual R01 grants typically ranging $250K-$500K annually.<ref>{{cite web |url=https://www.cancer.gov/about-nci/budget |title=NCI Budget |publisher=National Cancer Institute |access-date=February 22, 2025}}</ref> ==Staff== TEC lacks a distinct staff count; it relies on NCI Division of Cancer Biology personnel, supporting dozens of investigators across funded projects.<ref>{{cite web |url=https://www.cancer.gov/about-nci/organization/dcb |title=Division of Cancer Biology |publisher=National Cancer Institute |access-date=February 22, 2025}}</ref> ==Funding== TEC is funded through NCI’s extramural budget via NIH appropriations, primarily R01 grants under PAR-25-171, with no independent revenue.<ref>{{cite web |url=https://grants.nih.gov/grants/guide/pa-files/PAR-25-171.html |title=PAR-25-171 |publisher=National Institutes of Health |access-date=February 22, 2025}}</ref> ==Services provided== TEC supports tissue engineering research with funding, hosts collaborative workshops, validates biomimetic models, and facilitates data sharing among cancer researchers.<ref>{{cite web |url=https://www.cancer.gov/about-nci/organization/dcb/research-programs/tec |title=Cancer Tissue Engineering Collaborative |publisher=National Cancer Institute |access-date=February 22, 2025}}</ref> ==Regulations overseen== TEC does not oversee regulations but operates under NIH grant policies (e.g., 45 CFR Part 75).<ref>{{cite web |url=https://www.cancer.gov/grants-training/policies |title=Grants Policies |publisher=National Cancer Institute |access-date=February 22, 2025}}</ref> ==Headquarters address== The headquarters address, as listed on Google Maps, is 9609 Medical Center Drive, Rockville, MD 20850, USA, within NCI’s Shady Grove campus.<ref>{{cite web |url=https://www.cancer.gov/about-nci/organization/dcb |title=Division of Cancer Biology |publisher=National Cancer Institute |access-date=February 22, 2025}}</ref> ==History== Launched in 2016 via PAR-16-105 after NCI workshops (2012-2015) identified tissue engineering’s potential in cancer research, TEC grew from PS-ON insights, funding its first R01 cohort to address tumor microenvironment gaps.<ref>{{cite web |url=https://www.cancer.gov/about-nci/organization/dcb/research-programs/tec |title=Cancer Tissue Engineering Collaborative |publisher=National Cancer Institute |access-date=February 22, 2025}}</ref> ==External links== *[https://www.cancer.gov/about-nci/organization/dcb/research-programs/tec Official Website] *[[wikipedia:National_Cancer_Institute#Research]] *[https://physics.cancer.gov PS-ON Network] ==References== <references />